Agenus’ (AGEN) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Agenus (NASDAQ:AGEN) in a report released on Wednesday morning,Weiss Ratings reports.

Other analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Agenus in a research note on Wednesday, September 10th. Zacks Research raised Agenus to a “hold” rating in a research note on Tuesday, August 12th. Finally, Wall Street Zen downgraded Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $14.50.

Agenus Stock Down 6.6%

AGEN opened at $3.97 on Wednesday. The firm has a market cap of $126.48 million, a P/E ratio of -0.56 and a beta of 1.43. Agenus has a 52 week low of $1.38 and a 52 week high of $7.34. The business’s fifty day simple moving average is $4.42 and its 200 day simple moving average is $4.12.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The business had revenue of $25.70 million during the quarter, compared to analysts’ expectations of $49.71 million. As a group, equities analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently modified their holdings of AGEN. Siren L.L.C. purchased a new stake in shares of Agenus during the 1st quarter valued at about $752,000. Marshall Wace LLP acquired a new position in shares of Agenus in the 2nd quarter worth approximately $1,976,000. AQR Capital Management LLC grew its position in shares of Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after acquiring an additional 427,604 shares in the last quarter. Bank of America Corp DE grew its position in shares of Agenus by 110.0% in the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after acquiring an additional 220,327 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Agenus in the 2nd quarter worth approximately $906,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.